India Strengthens Regulation of GLP-1 Weight Loss Drug Supply Chain India’s drug regulatory authority has intensified its oversight of the distribution and use of GLP-1-based weight loss medications, launching a nationwide enforcement campaign to address illegal activities and ensure compliance with safety standards. The Central Drugs Standard Control Organisation (CDSCO), working alongside state Licensing Authorities (SLAs), has conducted comprehensive inspections and audits across multiple regions to target non-compliant practices, including improper dispensing and misuse of these drugs. The initiative aims to reinforce adherence to the conditions of approval and label warnings for GLP-1-based weight loss treatments. State drug controllers have been directed to enhance monitoring of the entire supply chain, from manufacturing to retail, to prevent unauthorized distribution. Authorities are also urged to collaborate with the Advertising Standards Council of India (ASCI) and other relevant bodies to ensure strict enforcement of regulations. Over the past several weeks, the campaign has focused on identifying and addressing violations in the distribution chain, which has raised concerns about the potential risks associated with these medications. The enforcement efforts include coordinated inspections of pharmacies, healthcare providers, and other entities involved in the supply of GLP-1 drugs. The regulator emphasized the need for strict compliance to protect public health and prevent the proliferation of counterfeit or substandard products. The move comes amid growing scrutiny of GLP-1 drugs, which have gained popularity for their effectiveness in weight management but also face challenges related to accessibility and misuse.#advertising_standards_council_of_india #pharmaceutical_sector #glp_1_drugs #central_drugs_standard_control_organisation #state_licensing_authorities
Laurus Labs shares are up 100% in the last 12 months and Motilal Oswal sees further upside Shares of Laurus Labs Ltd. rose on Thursday, February 26, as brokerage firm Motilal Oswal expressed confidence in the stock’s performance. The firm reiterated its 'buy' rating on the company, setting a price target of ₹1,280 per share. This target represents an 18.9% potential increase from the stock’s previous closing price, marking the highest estimate among analysts. Motilal Oswal highlighted the company’s strong execution compared to its peers in the contract development and manufacturing organization (CDMO) sector. The brokerage noted that Laurus Labs has delivered 30% year-over-year growth and maintained a 26% EBITDA margin in the first nine months of the current fiscal year. This performance is attributed to the company’s expansion in the CDMO and formulation segments. The brokerage also projected that Laurus Labs will achieve a Profit After Tax (PAT) of ₹850 crore by the end of the financial year 2026, with forecasts of ₹1,150 crore by 2028. These figures imply a compounded annual growth rate (CAGR) of 16% over the period. Motilal Oswal emphasized that the company’s ability to outperform peers is due to its resilience amid industry challenges, including program delays, destocking, and slower commercial conversions faced by some competitors. The analysis noted that while the CDMO sector has experienced an uneven recovery, Laurus Labs has demonstrated stronger financial results. The firm’s confidence is further supported by the company’s scale-up in key business areas, which has contributed to its improved margins and growth trajectory.#motilal_oswal #laurus_labs #cdmo_sector #pharmaceutical_sector #biotechnology_sector
